Precise Growth of Nucleic Acid Vaccine Market Impact of Existing and Emerging Flexible Trends and Top Key Players (Moderna, CureVac, Inovio, Sanofi, GSK, CNBG, Hualan Bio) | Future Outlook 2020-2025

Overview of Global Nucleic Acid Vaccine Market:

This report provides in-depth study of "Global Nucleic Acid Vaccine Market 2020" using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Nucleic Acid Vaccine Market report also provides an in-depth survey of key players in the market organization.

According to the market research study, the Nucleic acid-based diagnostics are extensively employed in laboratory settings to diagnose a wide range of medical conditions. Rapid growth in prevalence of cancer, infectious diseases, genetic disorders, and neglected tropical diseases surge the demand for isolation of DNA or RNA for the nucleic acid-based diagnostics, hence providing high-value avenues in the market for Nucleic Acid Vaccine.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/265950 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

In terms of the geographic analysis, North America accounted for the largest revenue share in 2019. The presence of food safety regulatory bodies for surveillance of processed food products in U.S., such as the FDA and the Food Safety and Inspection Service (FSIS), stipulate the DNA isolation procedures for each type of food product. APAC region is expected to witness the fastest growth rate in the near future. China is one of the attractive markets due to growth in DNA and RNA library preparation for next-generation sequencing in China.

Global Key Vendors:

1 Moderna

2 CureVac

3 Inovio

4 Sanofi

5 GSK

6 CNBG

7 Hualan Bio

8 Zhifei Shengwu

9 Liaoning Chengda

10 BioKangtai

11 CanSinoBIO

12 Walvax Biotechnology

13 Fosun Pharma and More...................

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Nucleic Acid Vaccine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/265950/single .

Product Type Segmentation

1 Preventive Nucleic Acid Vaccine

2 Therapeutic Nucleic Acid Vaccine

Industry Segmentation

1 Hospital

2 Clinic

3 Others

Latest Medical Industry News:

Moderna (April 27, 2020) - Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus - Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the company's mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2) to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which is expected to begin in the second quarter of 2020. This study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. Each subject will be assigned to receive placebo, a 50 ?g or a 250 ?g dose at both vaccinations. The company intends to enroll 600 healthy participants across two cohorts of adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300). Participants will be followed through 12 months after the second vaccination.

"Submitting this IND is an important next step in the clinical development of our mRNA vaccine against SARS-CoV-2, and we are moving rapidly to potentially address this global health emergency," said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. "We look forward to launching this Phase 2 study as soon as possible, which will provide important information about the safety, reactogenicity and immunogenicity of mRNA-1273."

Subject to data from the Phase 1 and Phase 2 studies and discussions with regulators, a Phase 3 study could begin in the fall of 2020. Funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, supported the planning for these studies and also will support the late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacturing.

"Safe, effective vaccines are critical to ending this pandemic and preventing future outbreaks of SARS-COV-2," said BARDA Acting Director Gary Disbrow, Ph.D. "The next steps announced today for this particular vaccine highlight the value of collaboration among government agencies including BARDA and NIAID, and the private sector, to move vaccines and other medical countermeasures forward as rapidly as possible."

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/265950 .

Major Points in Table of Contents:

Global Nucleic Acid Vaccine Market Report 2020

1 Nucleic Acid Vaccine Product Definition

2 Global Nucleic Acid Vaccine Market Manufacturer Share and Market Overview

3 Manufacturer Nucleic Acid Vaccine Business Introduction

4 Global Nucleic Acid Vaccine Market Segmentation (Region Level)

5 Global Nucleic Acid Vaccine Market Segmentation (Product Type Level)

6 Global Nucleic Acid Vaccine Market Segmentation (Industry Level)

7 Global Nucleic Acid Vaccine Market Segmentation (Channel Level)

8 Nucleic Acid Vaccine Market Forecast 2020-2025

9 Nucleic Acid Vaccine Segmentation Product Type

10 Nucleic Acid Vaccine Segmentation Industry

11 Nucleic Acid Vaccine Cost of Production Analysis

12 Conclusion

................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.